Today: 12 March 2026
Crocs stock slides 6% today — what Wall Street is watching next for CROX
30 December 2025
1 min read

Crocs stock slides 6% today — what Wall Street is watching next for CROX

NEW YORK, December 29, 2025, 23:17 ET — Market closed.

  • Crocs shares fell 6.2% on Monday to $85.94.
  • The stock lagged consumer discretionary peers despite a modestly lower broader market.
  • Traders are eyeing Fed minutes, jobless claims and Crocs’ next earnings update.

Crocs Inc shares closed down 6.2% on Monday at $85.94, giving back early gains and finishing near the day’s lows. Investing.com

The late-December drop lands as investors reset positions into year-end and start looking ahead to fourth-quarter results across retail and apparel. For Crocs, the focus is on whether demand holds up after the holiday period and whether margins can stay firm as promotions ebb and flow.

The next major checkpoint is Crocs’ quarterly report, expected on Feb. 12, according to Nasdaq. Investors will also be measuring results against the company’s adjusted earnings per share (EPS) guidance — a profit metric that excludes certain one-time items. Nasdaq

U.S. stocks ended lower on Monday, with the S&P 500 down 0.35% and the Nasdaq off 0.5% as big technology names retreated, Reuters reported. “This is (not) the beginning of the end of the tech dominance, it’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford Trust, in the same report, which noted Fed minutes and weekly jobless claims are among the week’s key macro events. Reuters

In consumer discretionary, the Select Sector SPDR ETF (XLY) fell about 1%, while Nike and Deckers Outdoor edged higher. Crocs’ decline stood out against that backdrop.

Crocs opened at $91.04 and traded as high as $91.68 before sliding to a session low of $84.88, according to market data. Roughly 2.1 million shares changed hands.

The company’s last earnings update came on Oct. 30, when it reported third-quarter revenue of $996 million, down 6.2% year-on-year, and guided fourth-quarter revenue to be down about 8% versus a year earlier. Crocs also said it expected adjusted EPS of $1.82 to $1.92 and pointed to additional cost savings while continuing share repurchases. Crocs Investors

Investors remain sensitive to the split between Crocs’ core brand and HEYDUDE, and to the balance between wholesale and direct-to-consumer (DTC) sales — sales through the company’s own stores and websites — as demand normalizes across the category.

Before Tuesday’s session, the week’s Fed minutes and jobless claims data are likely to set the tone for rate-sensitive parts of the market, especially with liquidity thinning into year-end.

For CROX, traders will be watching technical levels — price points that investors use as rough markers for where buying or selling has tended to show up. After Monday’s slide, the $85 area is back on the radar as near-term support, with the $90-$92 zone a key hurdle after the day’s early peak.

Absent fresh company news, the next meaningful catalyst remains the expected Feb. 12 earnings report, when investors will look for an update on demand, margins and management’s cost actions. Until then, CROX is likely to trade with broader consumer discretionary sentiment and any shifts in rate expectations.

Stock Market Today

  • Codexis (CDXS) Surpasses Q4 Earnings and Revenue Expectations
    March 11, 2026, 7:26 PM EDT. Codexis (CDXS) reported Q4 earnings of $0.11 per share, sharply beating the Zacks consensus estimate of $0.01 and reversing a year-ago loss of $0.13. Revenue reached $38.92 million, surpassing forecasts by 1.61% and nearly doubling last year's $21.46 million. The enzyme maker's earnings surprise stands at +2,100%, signaling improved financial health. Despite this, Codexis shares are down 23.9% year-to-date, trailing the S&P 500's 0.9% decline. The stock holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance amid mixed earnings estimate revisions. Upcoming management commentary and shifts in earnings forecasts will be crucial for investors. The wider Medical - Biomedical and Genetics sector ranks in the bottom 42%, suggesting sector challenges that could affect Codexis's trajectory.

Latest article

XRP Price Today: Ripple’s Australia License Push Keeps XRP Near $1.40

XRP Price Today: Ripple’s Australia License Push Keeps XRP Near $1.40

11 March 2026
XRP traded near $1.40, down 1.4% Wednesday, after Ripple announced plans to acquire BC Payments Australia to secure an Australian Financial Services Licence. The move comes as Australia tightens licensing rules for digital-asset firms. Broader crypto markets remained cautious amid concerns over oil prices, Iran, and U.S. inflation. Ripple’s deal is pending completion.
Natural Gas Price Today: Europe Gas Holds Firm as Brussels Weighs Cap After Qatar Shock

Natural Gas Price Today: Europe Gas Holds Firm as Brussels Weighs Cap After Qatar Shock

11 March 2026
European natural gas prices held near 48 euros per megawatt hour Wednesday as Shell declared force majeure on Qatari LNG cargoes, with disruptions expected to hit from April. Asia is bidding up for replacement fuel, while Brussels considers subsidies or a price cap. LNG Canada increased shipments, but analysts warn Europe’s gas storage could end March far below average if Qatari supply issues persist.
Bitcoin Price Today: BTC Holds Above $71,000 as ETF Inflows Return, Crypto Stocks Mixed

Bitcoin Price Today: BTC Holds Above $71,000 as ETF Inflows Return, Crypto Stocks Mixed

11 March 2026
Bitcoin traded above $71,000 on Wednesday, slipping to $71,065 after a session range between $69,014 and $71,271. U.S. spot bitcoin ETFs saw $246.9 million in inflows on March 10, with BlackRock’s IBIT leading daily gains. U.S. consumer prices rose 0.3% in February, while Brent crude rebounded 4% to $91. Crypto equities were mixed; Marathon Digital fell 2.3%, Coinbase edged up 0.3%.
Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes
Previous Story

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Coca-Cola Consolidated (COKE) stock slides nearly 4% into year-end — what traders watch next
Next Story

Coca-Cola Consolidated (COKE) stock slides nearly 4% into year-end — what traders watch next

Go toTop